Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Smart Search
The Effectiveness of Marine Based Fatty Acid Compound (PCSO-524) and Firocoxib in the Treatment of Canine Osteoarthritis
Authors:
This randomized double blinded study included 79 mixed breed dogs that had hip and/or stifle OA with X-ray confirmation. Outcome measures were changes in Kinetic force plate gait analysis-Peak Vertical Force (PVF), the Orthopedic Assessment Score (OAS), Canine Brief Pain Inventory score (CBPI), and serum prostaglandin E2 concentration (PGE2).
The results of the study suggest that within each group of a combination (PCSO-524 and Firocoxib), PCSO-524, Firocoxib showed the significant improvement of weight bearing ability but not in the comparison between.
The Effectiveness of Marine Based Fatty Acid Compound (PCSO-524) Alone and Combined with Firocoxib in the Treatment of Canine Osteoarthritis
(VOS conference, March 2018)
This randomized study involved 31 mixed breed dogs with x ray confirmed OA of stifle joint. They were split into 2 groups for four weeks of treatment.
The results showed a non-significant effect of the treatment on the adjusted Peak Vertical Force (PVF) value (p=0.447) among the 2 treatment groups.
The Effectiveness of Marine Based Fatty Acid Compound (PCSO-524) and Firocoxib in the Treatment of Canine Osteoarthritis.
This randomized double blinded study included 79 mixed breed dogs that had hip and/or stifle OA with X-ray confirmation. Outcome measures were changes in Kinetic force plate gait analysis-Peak Vertical Force (PVF), the Orthopedic Assessment Score (OAS), Canine Brief Pain Inventory score (CBPI), and serum prostaglandin E2 concentration (PGE2).
The results of the study suggest that within each group of a combination (PCSO-524 and Firocoxib), PCSO-524, Firocoxib showed the significant improvement of weight bearing ability but not in the comparison between.
Effectiveness of Disease Modifying Osteoarthritis Agents and Carprofen for Treatment of Canine Osteoarthritis
A prospective, randomized, single-blinded study was conducted to evaluate and compare the effectiveness of disease modifying osteoarthritis agents (DMOAAs) and carprofen by using force plate gait analysis and orthopaedic assessment score (OAS) in osteoarthritic dogs.
Forty dogs with hip and/or stifle osteoarthritis (OA) were assigned randomly into four treatment groups:
PCSO-524, treated with a marine-based fatty-acid compound; GC-ASU, treated with a combination of glucosamine-chondroitin sulphate and avocado/soybean unsaponifiables; CPF, treated with carprofen; and CPF-PCSO, treated with a combination of carprofen and PCSO-524. Each group received the therapeutic agent orally for four weeks.
Peak vertical force (PVF), OAS, haematology and blood chemistry values were evaluated before treatment, and on the second and fourth weeks post-treatment.
No significant effect was found in the PVF, OAS and blood values among the four treatment groups.
The Effectiveness of Marine Based Fatty Acid Compound and NSAIDs for the Treatment of Canine Osteoarthritis: a preliminary study
The Objectives of this study were to investigate the effectiveness of PCSO-524, NSAIDs and combination of NSAIDs and PCSO-524 in the treatment of canine osteoarthritis through the use of force plate gait analysis.
Study Design: A prospective block-randomized single-blinded study.
Animals: Thirty client-owned dogs that had clinical and radiographic evidences of hip or stifle osteoarthritis.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted
